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INTRODUCTION 
Stroke is known to human race since ancient time. The 7
th
 
century great Indian physician, Charaka described the stroke which 
he called “Pakshaghat” meaning hit one half of the body.  The 
other synonyms are ardhang or lakwa. According to Charaka, 
stroke affects either right or left half of body leading to impaired 
movement and function of that half of the body (hemiparesis) and 
difficulty in speaking which may be inability to talk (aphasia) or 
slurred speech (dysarthria).  He had also identified head as the vital 
organ, controlling the senses and nerve centers of the whole body.  
These meticulous observations of stroke symptoms are relevant till 
now. 
Stroke is one of the major causes of death and dependency 
among all the neurological disorders. According to World Health 
Organization (WHO) stroke is defined as rapidly developing 
clinical symptoms and / or signs of focal, at times global loss of 
cerebral function, with symptoms lasting more than 24 hours or 
leading to death, with no apparent cause other than of vascular 
origin. 
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The global prevalence of stroke is 5 to 8 /1000.  Globally 
stroke incidence is variable according to the ethnic differences in a 
common geographical location and ranged from 93 to 223/1,00,000 
population. Incidence of stroke in India is difficult to study due to 
multiple factors.   
The incidence rate of stroke in India was 13/1,00,000 in a 
study done at Vellore, in a population sample of  2,58,576 followed 
over two years. In another study conducted at Rohtak found that the 
stroke incidence was 33/1,00,000 (27/1,00,000 for first ever 
stroke).  The stroke risk increases steadily as the age advances.  
The term stroke is applied to a sudden focal neurologic syndrome,
1
 
caused by cerebrovascular disease. The vascular pathologic process 
may be considered not only in its grosser aspects-embolism, 
thrombosis, dissection, or rupture of a vessel-but also in terms of 
more basic or primary disorder, i.e., atherosclerosis, hypertensive 
arteriosclerotic change, arteritis, aneurysmal dilatation,  and 
developmental malformation. Most strokes are sudden onset of a 
focal neurologic deficit, as if the patient was "struck by the hand of 
God"
2
. Stroke is the one, which is common among many 
neurological disorders. Worldwide, stroke is one of the leading 
causes of death and a major etiology for adult disability. Stroke 
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poses serious problems with medical, rehabilitation and 
socioeconomic status. As the prevalence of disability due to stroke 
is expected to rise due to increase in population, this burden wil l 
still increase over the next 2 decades.  
Stroke is the one of the important causes of long term 
disability in a community setting as about 30 to 50% of stroke 
patients are left with residual deficits.  The hospital based studies 
had shown that 2% of all, 4 to 5 % of medical and 20% of 
neurological admissions were due to stroke.  The cost of stroke is 
difficult to calculate but the disability-adjusted life years (DALY) 
lost in India due to stroke in 1990 were 62,48,000 and estimates of 
deaths and DALYs lost due to stroke by 2020 are expected to be 
5,98,000 and 52,23,000 respectively.   
Strokes occur either in anterior circulation or posterior 
circulation. Posterior circulation supplies approximately one-fifth 
of the total brain. These areas include cerebellum, brainstem, 
occipital lobes, medial temporal lobes and thalamus. Posterior 
circulation is formed by 1 basilar artery, 2 vertebral arteries and 2 
posterior cerebral arteries
3
.  
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The concept of the ischemic penumbra started few decades 
ago. Penumbra is defined as an area of potentially salvagable, 
severely hypoperfused tissue around the ischemic core
4,5
. Only the 
cells in the penumbra, served by low residual perfusion, can be 
reversed within a reasonable time after the onset of stroke. The 
ischemic penumbra represents actively changing phenomenon. If 
occlusion of vessel persists, the penumbra may be merged with the 
core tissue
6
. On the other hand, it may return to a normalcy 
following neuroprotective interventions and vessel recanalization. 
It thus appears that the ischemic penumbra is in between normal 
tissue and core. 
The importance of early intervention in stroke has been and 
continues to be evolved. The important datas supporting the 
relevance of penumbra are the effects of early recanalization, 
thrombolytic agents or mechanical clot-removal devices. Some 
studies showed that penumbra is present even up to 24 hours
7
.  
To identify penumbra diffusion perfusion mismatch magnetic 
resonance imaging (MRI) is commonly used. Another alternative 
technique that is gaining attention is perfusion CT, which is faster, 
less expensive and widely available than MRI. NINDS-rtPA trial 
permitted intravenous thrombolysis up to three hours from the onset 
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of symptoms in acute ischemic stroke. But ECASS III trial 
extended the time limit up to 4.5 hours. This study is to evaluate 
the penumbra in stroke. 
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AIM OF THE STUDY 
1) To analyze the clinical profile of ischemic stroke. 
2) To analyze the risk factors of ischemic stroke. 
3) To study early imaging patterns in acute ischemic stroke. 
4) To study the existence of ischemic penumbra in acute 
ischemic stroke up to 24 hours. 
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REVIEW OF LITERATURE 
There are approximately 785,000 recurrent or new 
cerebrovascular events in the U.S. (600,000 being first events and 
185,000 being recurrent events) every year
8
. Among those 88% of 
are ischemic strokes.  
The incidence of stroke increases as the age advances. Old 
age is an important etiology for stroke. After 55 years of age, 
incidence of stroke doubles in every decade. Overall, incidence of 
stroke is 1.25 times higher in men than women. Up to the age of 75 
years men develop ischemic events at higher rates than women.  
RISK FACTORS FOR STROKE 
Risk factors may be classified as modifiable and non 
modifiable (Table-1). Non modifiable risk factors for stroke include 
older age, ethnicity, male gender, family history& prior history of 
stroke. Common modifiable lifestyle risk factors include cigarette 
smoking and illicit drug use. Non-lifestyle risk factors include low 
socioeconomic status, systemic hypertension, lipid derangements, 
heart diseases and asymptomatic carotid artery disease. Stroke 
secondary to sickle cell disease is one of the modifiable non-
lifestyle risk factors. Potentially modifiable risk factors include 
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hyperhomocysteinemia, diabetes mellitus and left ventricular 
hypertrophy. 
Systemic hypertension renders the individual to ischemic 
stroke by causing heart disease and promoting atherosclerosis. 
Modest reduction in systolic blood pressure of 10 to 12 mm Hg and 
5 to 6 mm Hg of diastolic blood pressure is associated with a 
reduction in stroke incidence by 38%
9
.The reduction of Systolic 
Hypertension in the old age group revealed a 36% reduction in 
nonfatal and fatal stroke over 5 years in the age group of 60-and-
older. 
Diabetes mellitus increases the risk of ischemic strokes by an 
estimated two- to fourfold as compared with non diabetic 
individuals.   The stroke secondary to diabetes may be caused by 
cardiac embolism, atherosclerosis of cerebrovasculature or 
hemodynamic abnormalities. Diabetes associated with systemic 
hypertension adds significant additional risk for stroke. Diabetic 
individuals with autonomic neuropathy and retinopathy appear to 
be particularly high risk for ischemic stroke. Elevated insulin level 
elevates the risk for atherosclerosis and may represent a forerunner 
for small-vessel disease of brain. Presently, there is no evidence 
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exists that tight blood sugar control or normal HbA1c levels 
decrease the risk of stroke occurrence or  recurrence
10
.
  
Table-1: Risk factors for stroke 
Non modifiable Modifiable 
Age  
Race/ethnicity  
Gender 
Genetics 
Family history  
 
Systemic hypertension 
Transient ischemic attacks 
Heart disease 
Aortic arch atheroma 
Previous stroke 
Asymptomatic carotid Stenosis 
Cigarette consumption 
Alcoholism 
Diabetes mellitus 
Hyperlipidemia 
Elevated fibrinogen 
Increased homocysteine 
Oral contraceptive use 
Low serum folate 
Increased anticardiolipin antibodies 
Obesity 
Elevated total cholesterol and elevated low-density 
lipoprotein concentration are well associated with atherosclerosis. 
Analysis have suggested that ischemic stroke risk increases with 
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raising serum cholesterol and the reduction in risk of stroke 
associated with HMGCoA reductase inhibitor (statin) therapies is 
related to reduction of LDL cholesterol
11
. The Long-Term 
Intervention with Pravastatin in Ischemic Disease study analyzed 
cholesterol lowering with pravastatin in patients with a previous 
unstable angina or myocardial infarction who had cholesterol levels 
between 155 to 271 mg%. This study showed an appreciable 
reduction in MI, cardiovascular deaths, cardiac revascularizations 
as well as a 20% reduction in the risk of stroke. MIRACL 
(Myocardial Ischemia Reduction with Aggressive Cholesterol 
Lowering Trial using Atorvastatin) revealed a 50% relative risk 
reduction in stroke among the high-risk coronary disease patients
12
. 
Atrial fibrillation, the most common cardiac arrhythmia in the 
general population, affects approximately about 1% of adults, is the 
most common cause of cardioembolic stroke, and is also a risk 
factor for future cardiovascular disease. Heart failure, arterial 
hypertension, transient ischemic attacks, age older than 75 years, 
diabetes mellitus and prior stroke increase the risk of embolism in 
patients with non valvular atrial fibrillation. The CHADS2 Score 
represents a validated quantification of risk, assigning 1 point each 
for congestive heart failure, hypertension, 75 years and above and a 
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history of DM; assigning 2 points each stroke and TIA
13
. The 
incidence of ischemic stroke increases with increasing CHADS 2 
scores. 
Warfarin therapy, with the International Normalized Ratio 
value adjusted between 2 and 3 significantly decreases the stroke 
risk in patients with non valvular AF by approximately 66%. High-
risk patients, regardless of age, benefit from warfarin therapy. Left 
atrial enlargement also increases the risk for stroke in men.  
Smoking is an important risk factor for stroke, peripheral 
vessel disease and coronary artery disease. Smoking is an 
independent risk factor for ischemic stroke in both sex of all groups 
and a major risk factor for atherosclerosis of carotid arteries in 
men. The stroke risk in smokers is two to three times higher than in 
nonsmokers.
14
 The mechanisms of enhanced atherogenesis by 
cigarette smoking are not completely understood but  may be 
reduced capacity of the blood to deliver oxygen, increased blood 
coagulability, cardiac arrhythmias and triggering of arterial 
thrombus formation and arterial spasm. There is a J-shaped 
association between ischemic stroke and alcohol consumption. 
Moderate consumption (two drinks a day) of alcohol evenly 
distributed throughout the week results in a reduced risk. On the 
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other hand heavy alcohol consumption is associated with an 
enhanced risk for stroke. Heavy drinking may also precipitate 
cardiogenic cerebral embolism. Active drinkers have an increased 
frequency of obstructive sleep apneas and more severe hypoxemia. 
Conversely, moderate alcohol intake may reduce the risk for 
ischemic events and may increase concentration of HDL. 
The prevalence of obesity (body mass index of 30 and above) 
is increasing worldwide. Obesity, especially truncal or abdominal is 
one of the major risk factors for cardiovascular events in both sexes 
of all ages. There is some evidence that physical exercise may 
reduce the risk of stroke. Atherosclerotic lesion at the carotid 
bifurcation is a common cause of stroke. Asymptomatic carotid 
stenosis of less than 75% carries stroke risk of 1.3% annually; 
whereas in patients with stenosis of more than 75%, TIA and stroke 
rate is 10.5% each year.  
Plaque composition may be one of the essential factors in the 
pathophysiology of carotid events. Structure of plaque rather than 
percentage of carotid artery stenosis is a crucial factor in the 
progression stroke. Ultrasonographic morphology of carotid artery 
plaque will identify the patients at high risk for stroke. Ulcerated, 
heterogeneous and echolucent plaques with a soft core are unstable 
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plaques. These unstable plaques carry significant risk for producing 
arterioarterial embolism. 
Patients who suffer transient ischemic attacks are having 
greater risk than normal individuals for stroke and death from 
vascular causes. The risk of stroke is approximately three times 
higher than normal individuals. Symptomatic carotid stenosis of 
greater than 70% is having an annual risk of stroke of 
approximately 15%. Approximately 10% to 15% of patients with 
stroke might have had transient ischemic events before their stroke. 
Patients who suffered a first stroke are at increased risk of stroke 
recurrence, especially in the early post stroke period. Patients who 
suffer a recurrent stroke have increased mortality and morbidity 
than patients with first stroke. 
Elevated hemoglobin concentration, hematocrit and elevated 
blood viscosity may increase the risk of ischemic stroke. 
Antiphospholipid antibodies are a marker for an elevated risk for 
thrombosis, including transient ischemic attacks and stroke, 
particularly in the age group of younger than 50 years
15
. Overall 
association of factor V Leiden mutation and arterial  thrombosis has 
not been fully understood. Increased von Willebrand factor is a risk 
factor of ischemic stroke.   
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Higher levels of fasting total homocysteine (normal value 5-
15 mM), a sulfhydryl containing amino acid, is associated with a 
higher risk for thrombotic events and stroke. The relative risk of 
ischemic stroke is increased in the users of high-dose estrogen oral 
contraceptives, particularly with coexisting cigarette smoking, 
hypertension and increasing age. The risk of thrombosis associated 
with pregnancy is higher in the postpartum period. The risk for 
ischemic infarction is elevated in the first 6 weeks after delivery 
but not during pregnancy. 
MECHANISMS OF STROKE 
Mechanisms responsible for ischemic events in acute stroke 
are as follows: 
1) Thromboembolism.  
2) Hemodynamic failure.  
The thromboembolism usually occurs as a result of embolism 
from other sources or in situ thrombosis and these lead to a steep 
fall in regional cerebral blood flow
16
. The hemodynamic failure 
usually occurs with arterial stenosis and occlusion. Strokes those 
occur through these two mechanisms are located particularly in the 
borderzones or watershed regions.  
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CARDIOEMBOLISM 
Cardioembolism contributes 20% to 30% of all ischemic 
cerebrovascular events
17,18
. Conditions those considered at elevated 
risk for embolization to the brain are sustained atrial flutter, atrial 
fibrillation, left atrial thrombus and recent anterior myocardial 
infarction
19
 etc… 
ARTERY-TO-ARTERY EMBOLISM  
Emboli can originate from large arteries in the neck
20
. This is 
an important mechanism of stroke due to large vessel 
atherosclerosis. It contributes for one fifth of all ischemic 
cerebrovascular events. 
SMALL VESSEL DISEASE:  
Thrombotic occlusion of the penetrating small arteries in the 
brain is another important etiology of strokes. Small vessel disease 
contributes about 20% to 30% of all ischemic events. This type of 
vascular lesion is having strong association with hypertension. This 
is pathologically characterized by microatheroma, lipohyalinosis, 
Charcot-Bouchard aneurysms and fibrinoid necrosis
21
. 
Microatheroma is an atheroma at the origin of small artery
22
.
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CELLULAR MECHANISMS OF ISCHEMIC NEURONAL 
INJURY IN ACUTE STROKE 
Neuronal cell death occurs due to the result of two different 
mechanisms:  
1) Necrosis  
2) Apoptosis.  
Necrosis is a process that results from acute permanent 
vascular occlusion. This is associated with inflammation, cellular 
swelling, damage of the vessels, membrane lysis and edema 
formation
23
.  
Apoptosis (programmed cell death) is characterized by 
chromatin clumping, cell shrinkage and cytoplasmic blebbing 
(Figure-2). There is no inflammation or secondary injury to the 
surrounding brain in apoptosis
24
. These two different types of 
neuron death represent opposite ends of a spectrum that is 
coexisting within the ischemic brain. 
Necrosis is the predominant cause of neuronal injury in the 
ischemic core, on the other end apoptosis being the major cause of 
neuronal injury in the penumbra. Because of the milder degree of 
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ischemia in penumbra, sufficient energy is produced for expression 
of new proteins that can mediate apoptosis.  
EXCITOTOXICITY, ACIDOSIS, INFLAMMATION,  
PERI-INFARCT DEPOLARIZATIONS 
The reduction in regional cerebral blood flow through 
inadequate delivery of the neuron’s oxygen, energy substrates and 
glucose, leads to inadequate production of energy results in 
dysfunction of ionic gradients across the membrane. Calcium influx 
is also enhanced by impairment in the energy-dependent reuptake 
of excitatory amino acids, particularly glutamate, and by the release 
of excitatory amino acids into the extracellular space (Figure-1).  
An elevated extracellular glutamate results in increased 
calcium influx, through the stimulation of the N-methyl D-aspartate 
or non-NMDA receptor
25
. Water also follows osmotic gradients, 
leading to intracellular edema. These result in recruitment of 
penumbra into the core. Effects of delayed edema formation 
(particularly vasogenic) include shift and displacement of brain 
structures, increased intracranial pressure, herniation and vascular 
compression
26
.
 
The intracellular calcium accumulation results in a series of 
events at both the nuclear and cytoplasmic levels that lead to cell 
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death through multiple mechanisms. Mitochondria is an essential 
source of reactive oxygen species. Mitochondrial membrane 
becomes leaky due to formation of mitochondrial permeability 
transition pore in the membrane of mitochondria
27
. This results in 
intra mitochondrial calcium accumulation, impaired energy 
production, mitochondrial swelling and formation of reactive 
oxygen species. Other consequences of disrupted mitochondrial 
permeability are the release of proapoptotic molecules.  
As sequelae to energy loss, potentials of membrane cannot be 
maintained. This results in depolarization of glia and neurons. In 
the core region depolarization is permanent. But in the penumbral 
area, the cells can repetitedly undergo depolarization, which is an 
active energy-requiring process. This repeated peri-infarct 
depolarization leads to the increase in the size of the infarct by 
further reduction in energy reserves
28
.
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Figure-1: Excitotoxicity 
 
Acidosis, resulting from ischemia, increases brain damage 
through the following mechanisms. 1. Edema formation. 2. 
Inhibition of lactate oxidation.3.Impairment of mitochondrial 
respiration. 4. Accumulation of hydrogen ions in the cell. 
Leukocytes, such as T lymphocytes, polymorphonuclear leukocytes 
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and natural killer cells also accumulate in the ischemic areas. The 
inflammatory cells accumulation occurs in the ischemic lesion due 
to accumulation of intracellular calcium, elevated oxygen free 
radicals, as well as hypoxia itself. The inflammatory cells also 
accumulate through adhesion molecules like selectins, integrins and 
immunoglobulins
29
. 
CONCEPT OF ISCHEMIC CORE AND ISCHEMIC 
PENUMBRA 
In acute ischemic stroke, according to the extent and duration 
of hypoperfusion, the parenchyma supplied by the occluded vessel 
is divided into  
1) Areas of irreversibly damaged brain tissue (ischemic core).  
2) Areas of brain tissue that are hypoperfused but viable 
(ischemic penumbra).  
The ischemic core is the tissue that is irreversibly damaged. 
Positron Emission Tomography studies in humans suggest that the 
ischemic core corresponds to cerebral blood flow values of less 
than 7  to 12 mL/100 mg/min
30
. The ischemic penumbra (Figure-3) 
is the tissue that is structurally intact but functionally impaired and 
hence potentially salvageable. It comprises of areas that are having 
a high cerebral blood flow limit of 17 to 22 mL/100 mg/min and a 
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low cerebral blood flow limit of 7 to 12 mL/100 mg/min. The aim 
of acute stroke therapy is  to salvag this penumbra by restoring its 
blood flow to non ischemic levels.  
Figure-2: Events in Apoptosis 
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Oligemia is the tissue that is mildly hypoperfused from the 
normal range down to 22 mL/100mg/min. It is well known that 
ischemic penumbra is a dynamic phenomenon. Penumbra evolves in 
time and space
31
. If vessel occlusion persists beyond particular 
time, the penumbra may shrink and progressively will be recruited 
into the core tissue. On the other spectrum, it may be recruited into 
normal tissue due to vessel recanalization or may be by 
neuroprotective therapy. 
Figure-3: Red - Core tissue, Green - Penumbra 
 
The penumbra is also electrophysiologically dynamic and 
undergoes repeated depolarizations. It is metabolically unstable, and 
is vulnerable to severe dissociation between metabolism and flow
32
.  
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Time limit of acute stroke therapy targeted at vessel 
recanalization is 4.5 hours from onset of symptoms for intravenous 
thrombolysis and 6 hours for intra-arterial thrombolysis. This is 
based on the concept that the penumbra has a short lifespan. It is 
rapidly incorporated into the core within few hours of the ictus if 
appropriate steps are not taken. 
Figure-4: Showing Diffusion Perfusion Mismatch 
 
Recent evidence reveals that penumbral brain tissue of 
significant extent is present even after 6 hours of onset of the stroke 
symptoms. Positron Emission Tomography studies using 
quantitative cerebral blood flow assessment or markers of tissue 
hypoxia like 18F fluoromisonidazole to assess penumbra were 
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done
33
. These studies included patients within 6 hours to as late as 
51 hours after the onset of stroke.  
Many investigators evaluated the penumbra based on 
diffusion/perfusion MRI (diffusion-weighted imaging/perfusion-
weighted imaging) mismatch in acute stroke. Using MRI 
technology, Schlaug and colleagues estimated that the penumbra 
comprises about 40% of the ischemic territory in a cohort of 
patients studied within 24 hours of symptom onset. The presence of 
diffusion/perfusion mismatch is highly confirming the presence of 
large vessel occlusion like internal carotid artery and middle 
cerebral artery.  Nowadays pathophysiology of acute stroke is 
related to reversible versus irreversible brain tissue. Hence a study 
in which a similar group of patients with stroke due to 
angiographically proven M1 middle cerebral artery occlusion were 
analyzed within 6 hours of stroke symptom onset with xenon- CT-
CBF technology
34
. In this study, core and penumbra were estimated 
based on established perfusion thresholds. Approximately it 
corresponds to one-third of the MCA territory. On the contrary, the 
ischemic core was highly variable, ranged from 20% to 70% of 
cortical middle cerebral artery territory. 
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IMAGING IN STROKE 
Patients who are admitted within 4.5 hours after the onset of 
stroke may be suitable candidates for intravenous thrombolysis.  CT 
Brain is usually sufficient to guide routine thrombolysis. Patients 
arriving after this time window may be candidates for trials like 
testing for extended time windows for thrombolysis or various 
other experimental reperfusion strategies.  CT brain scanning is the 
cost-effective strategy for imaging in those patients. But it is not 
sensitive for old haemorrhages. Overall, CT is less sensitive than 
MRI, but almost equally specific for early ischemic changes.  
DIFFUSION-WEIGHTED IMAGING (DWI)  
Some centres use MRI as the first line investigation for acute 
stroke. MRI with diffusion-weighted imaging has the advantage of 
superior sensitivity for early ischemic changes than computed 
tomography. MRI is especially important in acute stroke patients 
with rare presentations, abnormal stroke varieties and uncommon 
etiologies. MRI is also useful in whom a mimic of stroke is 
suspected but not clarified on CT Brain. 
MECHANISMS FOR DECREASED DIFFUSION IN ACUTE 
STROKE 
 There is failure of sodium potassium ATPase and other ionic 
pumps. So that there is total loss of ionic gradients across cell 
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membranes. Hence there is net diffusion of water from the 
extracellular space to the intracellular space. So volume 
changes occur both in intracellular and extracellular spaces.  
 The is decrease in the size of the extracellular space is due to 
expansion of intracellular space. Due to the decreased 
extracellular space there is excess tortuosity of the 
extracellular occurs.  
 Because of the breakdown of the cytoskeleton and organelles 
there is increased intracellular space tortuosity and 
intracellular viscosity occurs.  
 Finally cell membrane permeability is also enhanced35.  
Diffusion weighted MRI imaging is the gold standard 
investigation of choice to detect core tissue of the infarct (Figure-
5). The sensitivity and specificity of DWI imaging is more than 
95% in best stroke centers
36,37
. The false-negative results (not 
detected by Diffusion weighted MR imaging) can occur in 
brainstem (particularly in the medulla) or deep gray nuclei. The 
volume of DWI lesion is well correlating with clinical outcome 
scales. Indicators of poor outcome:  
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1) The volume of DWI lesion is greater than 1/3 of the expected 
middle cerebral artery territory. 
2) The volume of core tissue is more than 100 ml.  
Figure-5: Acute ischemic stroke in DWI and PWI 
 
Intravenous recombinant tissue plasminogen activator is 
permitted to use within 4.5 hours of stroke as per European 
Cooperative Acute Stroke Study. The MERCI retrieval device is 
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permitted to use within 9 hours after the onset of stroke symptoms. 
For acute stroke, currently these are the two treatment options 
approved by the Food and Drug Administration. 
CT PERFUSION 
CT perfusion expands the role of CT to study the acute 
stroke. CT perfusion will assess the cerebral hemodynamics. It will 
also determine the consequences of vessel occlusions and stenosis. 
So CT perfusion has got complement role than CT Angiogram. By 
using CT Perfusion both the ischemic core tissue and penumbra 
tissue may be evaluated.  
Advantages of CT Perfusion  
 It is fast38.  
 Easily available.  
 Safe if done correctly. 
 Cost effective39.  
 Time required to do CT Perfusion is extra 5 minutes after 
completing non contrast CT Brain.  
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 No need to delay in administering IV thrombolysis, which 
may be administered at the CT scanner table immediately 
after the completion of the non contrast CT Brain
40
.  
 CT Perfusion is comparable with diffusion weighted imaging 
and perfusion weighted MR imaging in serving to evaluate 
stroke severity.  
Because of the above advantages CT Perfusion imaging 
would have essential implications in the management of 
cerebrovascular accident patients globally. Core is typically defined 
as the cerebral tissue that is irreversibly damaged at presentation, 
even after early revascularization procedures. On the other hand 
Penumbra is defined as functionally poorly perfused but potentially 
salvageable by recanalization procedures.  
Figure-6: DWI and MR perfusion images 
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The figure 6 is showing: (A) Diffusion-weighted imaging 
(DWI) of the left frontal infarct. Hemodynamic maps from the MR 
perfusion study are obtained at the same time: (B) cerebral blood 
flow (CBF), (C) cerebral blood volume (CBV), (D) mean transit 
time (MTT), and (E) Tmax. Within the infarct core, a markedly 
reduced CBV and CBF and markedly elevated MTT and Tmax are 
seen. Posterior to the infarct core (the DWI lesion), in the left 
temporal parietal region, a region with less severely reduced CBF 
and less severely prolonged MTT and Tmax is seen, consistent with 
the penumbra. 
MISMATCH 
Mismatch is defined as the difference between location and 
volume between the core tissue and penumbra tissue. Currently 
measured penumbra very often includes the benign oligemia 
regions also. Benign oligemia is defined by other CT Perfusion 
parameter like TTP (Time to Peak). A mismatch of greater than 
20% is typically considered as a clinically significant penumbra. 
This parameter is used for both clinical management and research 
purposes. Major trials using this operational definition include 
1.Diffusion-weighted imaging Evaluation for Understanding Stroke 
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Evolution (DEFUSE) trial. 2.Echoplanar Imaging Thrombolytic 
Evaluation Trial (EPITHET).   
May be the potential indications for CT Perfusion imaging in 
the near future, in the first 9 to 12 hours after stroke onset include:  
 Extension of the window period for intravenous thrombolysis 
beyond 4.5 hours and for intra arterial thrombolysis beyond 6 
hours for anterior circulation.  
 Exclusion of those patients most likely to have hemorrhage.  
 Inclusion of those patients who are likely to be benefitted 
from thrombolysis. 
 For the acceptable management of wake-up strokes, in which 
the accurate time of onset of the stroke is not known.   
 CT Perfusion can be used as triage therapies, such as 
hyperoxia administration and hypertension.  
CAROTID IMAGING 
Current trend in carotid atheroma, whether to treat medically 
or surgically is based upon the degree of stenosis and 
symptomatology. In symptomatic patients, various large controlled 
trials like North American Symptomatic Carotid Endarterectomy 
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Trial [NASCET], European Carotid Surgery Trial [ESCT] have 
proved the advantage of carotid endarterectomy over the medical 
management. In individuals with milder degrees of stenosis (<50%) 
the favorable treatment plan is medical management. In patients 
with70%–99% stenosis the ideal treatment is surgical treatment.41 
The risk of recurrence following a transient ischemic attack is as 
high as 9% within the first one week. Hence a more aggressive 
surgical strategy is needed to treat individuals within 2 weeks of 
symptom onset.
42
 The Asymptomatic Carotid Atherosclerosis Study 
(ACAS) and the Asymptomatic Carotid Surgery Trial (ACST) 
randomized the patients between medical therapy and carotid 
endarterectomy (>60% stenosis in ACAS, >70% in ACST). They 
also showed a similar lower rate of stroke or death in the surgically 
treated patients. 
LUMINAL IMAGING 
ULTRASOUND 
One of the most widely available and used methods to assess 
carotid disease is ultrasound (US). (1) B-mode (2) Doppler 
ultrasound. Most of the time both these methods are combined.  
With B-mode US visualization of the lumen and the vessel wall can 
be done. So luminal diameters can be evaluated. DUS depends upon 
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the measurement of blood velocity. So the degree of stenosis can be 
assessed. 
COMPUTED TOMOGRAPHY ANGIOGRAPHY 
Computed Tomography Angiographyis a good alternative to 
MRA in selected group of patients. Computed tomography 
angiography (CTA) is a good noninvasive investigation for carotid 
imaging.  
Advantages of CT Angiography  
1) Rapidity in time.  
2) Large anatomic coverage from the aortic arch to the circle of 
Willis.  
3) Minimally invasive procedure. 
4) Requires only peripheral venous injection of iodinated 
contrast media.  
5) It can also be used to detect other features of plaque such as 
ulceration, which is an evidence of vulnerability for the 
disease
43
.
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MAGNETIC RESONANCE ANGIOGRAPHY 
Contrast-enhanced magnetic resonance angiography is 
gaining popularity due to its high sensitivity and specificity almost 
comparable with Digital Subtraction Angiography
44
. Like CT 
Angiography, MRA is a minimally invasive procedure. Contrast -
enhanced MRA produces high-quality images with an extensive 
anatomic coverage, without ionizing radiation. 
The SAPPHIRE trial (Stenting and Angioplasty with EPD in 
Patients at High Risk for Endarterectomy) was a prospective trial 
with randomization of high-risk asymptomatic and symptomatic 
patients to Angioplasty and stenting of carotid arteries or carotid 
endarterectomy. Clinical follow-up at 3 years showed no significant 
differences between patients with carotid stenting carotid 
endarterectomy. 
Carotid Angioplasty and Stenting is an approved treatment by 
the U.S. Food and Drug Administration (FDA). CAS is useful in 
patients with high risk for surgery (symptomatic who are having 
≥50% stenosis and asymptomatic individuals with ≥80% stenosis). 
CAS is an approved (reasonable and necessary) for high-risk 
symptomatic patients with 70% or greater stenosis. The advantages 
of CAS over CEA are that it does not require general anesthesia, 
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the patient’s neurological status can be assessed during the 
procedure, recovery time is shorter, and there is no need for a neck 
incision (risks of cervical hematoma and cranial nerve injuries).  
INTRAVENOUS (IV) THROMBOLYSIS 
Till now, Intravenous thrombolytic therapy is the cornerstone 
of evidence-based acute ischemic cerebrovascular accident therapy. 
Unfortunately, even after the approval of thrombolytic therapy from 
1996, the IV rt-PA had been used in only 2% to 8.5% of patients 
with acute ischemic stroke. IV rt-PA is efficacious and cost-
effective treatment for individuals with acute ischemic stroke who 
are treated within 3 hours of symptom onset
45
. Only 6.6% of 
individuals suffer from severe complication such as symptomatic 
intracranial hemorrhage (sICH)
46,47
.  
Studies to be performed in the Emergency Department  
 Noncontrast CT Brain or MRI Brain (without delay)  
 Serum electrolytes 
 Blood sugar 
 Electro cardiogram  
 Kidney function analysis 
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 Cardiac enzymes 
 Complete blood count with platelet counts  
 Oxygen saturation 
 Activated partial thromboplastin time (aPTT) 
 International normalized ratio (INR)  
If there is no suspicion of abnormalities in these values, therapy 
should not be withheld while waiting for the results
48
.  
Eligibility Criteria for IV rtPA Therapy:
49 
 Diagnosis of ischemic stroke which caused measurable 
neurologic deficit 
 No minor Neurologic signs  
 Symptoms not suggestive of subarachnoid hemorrhage 
 No spontaneous clearance of the neurologic signs  
 No urinary tract or gastrointestinal hemorrhage in the past 3 
weeks 
 Onset of symptoms should be less than 4.5 hours before the 
start of treatment 
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 No major surgery in the past 2 weeks 
 No arterial puncture at a non compressible site in the past 1 
week 
 No prior stroke, head trauma or myocardial infarction in the 
past 3 months  
 No previous history of intracranial hemorrhage  
 No urinary tract or gastrointestinal hemorrhage in the past 3 
weeks 
 There should be no evidence of acute trauma or active 
bleeding 
 CT showing no multilobar infarction (hypodensity exceeding 
more than 1/3 of cerebral hemisphere)   
 Patient should  not take an oral anticoagulant or, if taking 
anticoagulants, international normalized ratio should be 
below 1.7 
 If patient has received heparin in the past 2 days, aPTT 
should be in the normal range 
 Platelet count should be above 1lakh/ mm3 
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 Blood sugar should be above 50 mg/dL  
 Blood pressure should be kept under control. (systolic BP 
should be less than185 mm Hg and diastolic BP should be 
less than110 mm Hg) 
 Family members  or Patient must understand the potential 
benefits and risks  of therapy 
Monitoring of the patient during and after Treatment 
During IV rtPA administration symptomatic ICH can occur. 
So it is prime importance to prevent and identify sICH during the 
rt-PA administration. Monitoring should be done up to 24 hours 
after administration. Frequent monitoring of vitals, clinical and 
neurologic condition is recommended. The patient should be 
assessed once in every 15 minutes during the rt-PA administration. 
Thereafter monitoring should be done once in every 30 minutes for 
the next 7 hours, and once in 60 minutes for the next 16 hours. If 
the blood pressure is more than 180/105 mm Hg, it should be 
immediately treated. Treatment of hypertension after rt-PA infusion 
should be more aggressive than the period prior to initiation of rt -PA.  
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Alarming symptoms and signs are the following 
 Nausea or vomiting 
 New onset headache or worsening of the preexisting headache  
 Worsening of the pre existing neurologic deficit  
 A new neurologic deficit  
If the above symptoms and signs are found, the rt-PA infusion 
should be discontinued.  Urgent CT Brain should be done to rule 
out symptomatic ICH. Treatment of the above complication is 
urgent transfusion of 6 to 8 units of platelets and cryoprecipitate.  
EXTENSION OF THE TIME WINDOW: ECASS III TRIAL 
The design of ECASS III had some variation from NINDS 
rtPA trial. Three notable differences between these 2 trials mainly 
found in the exclusion criteria. 
 If the age is greater than 80 years rt PA will not be given 
 If NIHSS score is greater than 25 rt PA will not be given 
 History of diabetes with prior Stroke is also excluded.  
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The results of the ECASS III trial have confirmed the safety 
and efficacy of IV rt-PA
50
. This study allowed toextend the upper 
limit of time for IV thrombolysis from 3 hours to 4.5 hours.  
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MATERIALS AND METHODS 
This study was conducted from May 2011 to January 2013. 
Patients were taken from Rajiv Gandhi Government General 
hospital. They were enrolled in this study after getting a written 
consent.  
INCLUSION CRITERIA 
1) Patients who presented with symptoms and signs of ischemic 
stroke. 
2) Patients who presented only with anterior circulation stroke. 
3) Patients who presented within 24 hours after the onset of 
stroke symptoms. 
EXCLUSION CRITERIA 
1) Patients who presented with symptoms and signs of 
hemorrhagic stroke. 
2) Patients who presented with posterior circulation stroke. 
3) Patients who presented more than 24 hours after the onset of 
stroke symptoms. 
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4) Patients who were not eligible for computed tomography (CT) 
perfusion study. 
5) Patients who were having contraindications to Magnetic 
Resonance Imaging. 
Patients who presented with stroke symptoms and signs were 
subjected to plain CT Brain. If the CT Brain ruled out hemorrhagic 
stroke, then the patient was subjected to diffusion weighted image 
(DWI) sequence of Magnetic Resonance Imaging (MRI) and CT 
perfusion after analyzing the renal functions. In DWI MRI imaging 
ischemic core tissue was assessed. In CT perfusion imaging 
penumbra tissue was assessed. After doing Diffusion Perfusion 
mismatch, presence of potentially salvageable penumbra was 
assessed. 
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OBSERVATION AND RESULTS 
In this study forty (40) patients were enrolled who were 
diagnosed to have anterior circulation acute ischemic stroke. All 
the patients were present within 24 hours after the onset of stroke 
symptoms. 
SEX DISTRIBUTION 
In this study, out of 40 patients 31 (77.5%) were males and 9 
(22.5%) were females (Figure-7). 
Figure-7: Sex distribution 
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AGE DISTRIBUTION 
In this study, out of 40 patients, 5 (12.5%) patients were in 
the age group of less than 40 years of their age. 12 (30%) patients 
were between 40 to 60 years of age. 23 (57.5%) patients were 
above 60 years of age (Table-2 and Figure-8). 
Table-2: Age distribution 
Age No. of patients 
< 40 years 5 
40 to 60 years 12 
>60 years 23 
 
Figure-8: Age distribution 
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HYPERTENSION 
Out of 40 patients, 22 (55%) were already known 
hypertensive patients. All of them were on regular treatment. 
Among them 5 were female patients and the remaining 17 were 
male patients (Table-3 and Figure-9). 
Table-3: Hypertension 
Sex No. of patients 
Male 17 
Female 5 
 
Figure-9: Hypertension 
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DIABETES MELLITUS 
In 40 stroke patients, 11 (27.5%) had diabetes mellitus. Out 
of 11 patients 9 were on regular treatment and rest of the 2 patients 
were not on regular treatment. Among them, 7 patients were males 
and remaining 4 of them were females (Figure-10). 
 
Figure-10: Diabetes Mellitus  
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CAROTID STENOSIS 
Out of 40 patients, 8 (20%) had carotid stenosis. 5 (12.5%) 
patients had 50 to 70% stenosis. Rest of the 3 (7.5%) patients had 
>70% stenosis (Table-4 and Figure-11). 
Table-4: Carotid stenosis and sex distribution 
% of stenosis 
No. of patients 
Male Female 
50 to 70% 3 2 
>70% 2 1 
 
Figure-11: Percentage of carotid stenosis distribution 
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CORONARY ARTERY HEART DISEASE 
5 (12.5%) patients were having coronary artery heart disease. 
One of them was diagnosed after admission (table-5). 
Table-5: Carotid artery stenosis 
Sex Total CAHD 
Male 31 2 
Female 9 3 
HYPERLIPIDEMIAS 
In this study out of 40 patients, 8 (20%) patients had 
hyperlipidemias. Out of 8 patients, 3 being female patients and rest 
of the 5 were male patients (Table-6 and Figure-12). 
Table-6: hyperlipidemias 
Sex Total Hyperlipidemias 
Male 31 5 
Female 9 3 
Figure-12: Hyperlipidemias 
Non-
hyperlipidemias 
80% 
Hyperlipidemias 
20% 
Hyperlipidemias 
 
  49 
SMOKING 
In this study 13 (32.5%) patients were chronic smokers. All 
of them were male patients (Figure-13). 
Figure-13: Smoking 
18 13 
0 5 10 15 20 25 30 35
Smoking
Non-smokers
Smokers
 
ALCOHOLISM 
Out of 40 patients, 7 patients were chronic alcohol users. One 
of them was a female patient (Figure-14). 
Figure-14: Alcoholism 
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PREVIOUS HISTORY OF STROKE 
2 patients had recurrence of cerebrovascular accident. Both of 
them were male patients. 
SIDE OF THE STROKE 
In this study, 23 patients had right sided hemiparesis (left 
sided ischemia) or hemiplegia whereas remaining 17 had left sided 
weakness (right sided ischemia).  
Out of right sided stroke patients, 19 were male patients and 4 
were female patients. Out of 17 left sided stroke patients, 12 were 
male patients and 5 were female patients (Figure-15). 
Figure-15: Side of stroke 
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Table-7: Territory of stroke 
Side of the weakness ACA Territory MCA Territory 
Right 4 19 
Left 4 13 
Out of 23 right sided ischemic stroke patients, 4 had ischemia 
in the anterior cerebral artery territory. Out of 17 left sided 
ischemic stroke patients, 4 had ischemia in the anterior cerebral 
artery territory (Table-7). 
NIHSS SCORE 
The mean average of the score of 40 patients was 9.225. The 
lowest score in this study was 4, whereas highest score was 17. 
Number of patients who presented with various NIHSS scores were 
as follows: ≤ 4 - 4 patients, 5to10 - 19 patients, 11 to 15- 16 
patients and 16 t0 20- 1 patient (Figure-16). 
Figure-16: NIHSS Score 
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TIME OF IMAGING 
Imaging was taken only in 1 patient within 4.5 hours. In 8 
patients imaging was taken from 4.5 to 10 hours. In rest of the 31 
patients imaging was taken from 10 to 24 hours after the onset of 
stroke symptoms (Figure-17 and Table-8). 
Figure-17: Time of Imaging 
<4.5 Hours, 1 
4.5 to 10 Hours, 8 
>10 Hours, 31 
 
Table-8: Time of Imaging and Penumbra 
Time of Imaging Number of Penumbra positive patients 
<4.5 Hours 1 
4.5 to 10 Hours 6 
>10 Hours 2 
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EARLY CT SIGNS 
In this study, 11 patients had normal CT Brain. All other 
patients had early signs of ischemic stroke or infarct itself (Table -9 
and Figures 18-20). 
Table-9: Early CT Findings 
Sex 
Early CT findings 
Present Absent 
Male 23 8 
Female 6 3 
Figure-18: Hperdense MCA Sign 
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Figure-19: Normal CT with DWI showing acute infarct 
 
Figure-20: Early CT Findings 
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PENUMBRA 
In this study all patients had core tissue in diffusion weighted 
MR imaging. But only in 9 patients, penumbra was present in 
diffusion perfusion mismatch. Out of 9 patients 3 were female 
patients. Rests of the 6 were male patients (Figure-21). 
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Figure-21: Sex distribution of Penumbra 
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Figure-22: CT Perfusion showing penumbra 
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DISCUSSION 
The risk factors of stroke are classified as modifiable and non 
modifiable.  Male sex & older age are non-modifiable risk factors.
51
   
Hypertension, diabetes mellitus, dyslipidemia, elevated body mass 
index, chronic smoking, ischemic heart disease, atrial fibrillation, 
rheumatic heart diseases are important modifiable risk factors.  
In this study 40 patients were included and analyzed. It is 
known that stroke risk doubles with each decade past age 55 years. 
Youngest patient in this study was 24 years, whereas oldest patient 
was 82 years old. Mean age of this study was 57.2 years. In this 
study 5 patients were in the age group of < 40 years, 12 patients 
were in the age group of 40 to 60 years and remaining 23 patients 
were in the age group of >60 years. Among the female patients, 
nobody was in the age group of < 40years, only 3 patients were in 
the age group of 40 to 60 years and the rest of 6 female patients 
were having > 60 years. As for as the age is concerned, average age 
of onset of stroke was 51.7 years in PROCAM study,
52
 65.94 years 
in Narupat Suanprasert et al study
53
. But in this study the age group 
was in between these two studies (Table-10). The comparison of 
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risk factors between those studies and our study is shown in table 
below. 
Table-10: Age comparison with other studies 
Name of the study PROCAM 
Narupat 
Suanprasert 
This 
study 
Average age (years) 51.7 65.94 57.2 
In this study 77.5% patients were male patients. 22.5% 
patients were female patients. In the study done by Naraput 
Suanprasert et al 64.2% patients were male patients whereas 35.8% 
patients were female patients. So in our study there was a slight 
male preponderance comparing with the above mentioned study 
(Table-11). 
Table-11: Sex comparison with other studies 
Sex Naraput Suanprasert This study 
Male 64.2 77.5 
Female 35.8 22.5 
In this study 22 (55%) patients were known hypertensives. 
Among them 17 were male patients and rest of the 5 were female 
patients. Among them 19 were on regular treatment and 3 patients 
were on not on regular treatment. Average systolic and diastolic 
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pressures in this study were 153.35 mmHg and 90.5 mmHg 
respectively. Hypertension was present in 71% (Huan et al),
54
 
57.9% (Teng Yeow Tan et al),
55
 56% (Naraput Suanprasert et al) 
and 43% (PROCAM) those studies. This study was almost 
comparable with Teng Yeow Tan et al and Naraput Suanprasert et 
al studies but there is slight variation from Huan et al and 
PROCAM studies. Average blood pressure (systolic-153.5, 
diastolic-90.5) in this study was comparable with PROCAM 
(systolic-149.5, diastolic-93.3) study. 
In this study 11 (27.5%) patients were already known diabetic 
patients. Among those 7 were male and 4 were female patients. All 
of them were on regular treatment. Average admission blood sugar 
in this study was 162.6 mg%. Number of diabetic patients in 
various studies were 38.7% (Huan et al), 27.6% (Teng Yeow Tan et 
al), 41.8% (Naraput Suanprasert et al) and 7.7% (PROCAM). This 
study value is comparable with Teng Yeow Tan et al study, whereas 
there is minimal variation from Naraput uanprasert et al and Huan 
et al and gross variation from PROCAM study groups (Table-12). 
In this study 7 patients were having both Diabetes mellitus and 
hypertension. Among them 4 (Total-31) were male and 3 (Total-9) 
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were female patients. The comparison of risk factors between their 
studies and our study is shown in table below. 
8 (20%) patients were having significant carotid stenosis 
(>50%) in this study. This study varies from Naraput uanprasert et 
al (43.3%) study. Among those 8 patients 5 (Male-3 and Female-2) 
were having 50 to 70% stenosis and 3(Male-2 and Female-1) were 
having >70% stenosis. 
Table-12: Risk factors comparison 
Name of the study Hypertension Diabetes mellitus 
This study 55% 27.5% 
Huan et al 71% 38.7% 
Teng Yeow Tan et al 57.9% 27.6% 
Naraput Suanprasert et al 56% 41.8% 
PROCAM 43% 7.7% 
In this study 5 (12.5%) patients were having coronary artery 
heart disease. Among them 2 were male and 3 were female patients. 
There were 19.4% (Huan et al) and 14% (Teng Yeow Tan et al) 
patients having coronary artery heart disease in the above 
mentioned studies. This study also was correlating with the above 
mentioned studies. 
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In this study 8 (20%) were having hyperlipidemias. Among 
those 5 were male and 3 were female patients. Out of the 8 patients, 
5 had elevation of both cholesterol and LDL, 2 had only elevation 
of LDL and 1 had elevation of both cholesterol and triglycerides.  
In this study 13 (32.5%) patients were chronic smokers. All 
of them were male patients. Various studies showed the following 
results- Huan et al -38.7%, Teng Yeow Tan et al-24.6%, PROCAM-
33.6%. This study is almost comparable with the above mentioned 
studies. 
7 (17.5%) patients were chronic alcohol consumers in this 
study. One patient was a female patient and rests of the 6 patients 
were male patients. Alcohol consumers in various other studies 
were 7.5% in Teng Yeow Tan et al study and 17.4% in %, 
PROCAM study. This study was correlating with PROCAM study 
but higher than Teng Yeow Tan et al study. 
Recurrence of stroke was noted in 2 of our patients. Both of 
them were male patients. 
There are various modalities of treatment available apart from 
IVrtPA for acute stroke therapy such as intraarterial thrombolytic 
therapy, MERCI retrieval device, PENUMBRA device,
56
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sonothrombolysis and various stenting and angioplasty methods. 
Hence it is very important task to identify the salvageable tissue in 
the acute stroke settings. 
There are various studies conducted for extending the time 
window for thrombolysis such as EPITHET
57
 (use of tPA from 
3–6 h), DEFUSE58 (use of tPA from 3–6 h), DIAS,59 DIAS-260 
and DEDAS
61
 (use of  Desmoteplase from 3to 9 hours). But only 
few studies evaluated the presence of penumbra after the time 
window. Various devices used in stroke patients are Merci, 
Penumbra, Wingspan, Solitaire and Trevo. For all these 
procedures and devices it is mandatory to look for the presence 
of penumbra. 
In this study out of 40 patients, 9 (22.5%) had penumbra up to 
24 hours after the onset of stroke symptoms. Among the 9 
patients, 3 were female patients and the remaining 6 were male 
patients. The lowest time was 4 hours and highest time was 21 
hours after the onset of the symptoms among the penumbra 
positive patients.  The mismatch was found in 53% in EPITHET 
study and 51% in DEFUSE study (But the upper limit of imaging 
in both these studies was only 6 hours after the onset of  stroke 
symptoms). In the study done by Jane Prosser et al , 74% of the 
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patients  had penumbra from 0 to 6 hours and 44% of the 
patients had penumbra from 6 to 24 hours. In a paper published 
by READ et al, they documented the presence of penumbra from 
6 hours to as late as 51 hours after the onset of stroke symptoms. 
Similarly Schlaug and colleagues in their paper in 1999 
demonstrated the penumbra within 24 hours after the symptom 
onset. 
 Among the penumbra positive patients, 1 was in the age 
group of < 40 years, 7 were in the age group of 40 to 60 years 
and 1 was in the age group of >60 years. In this study 3 out of 9 
female patients (33.3%) were having penumbra whereas 6 out of 
31 male patients (19.35%) were having penumbra. All the 9 
patients had only middle cerebral artery strokes.  
Among the 9 patients, hypertension was present in 2, diabetes 
was present in 1, coronary artery heart disease was present in 1, 
dyslipidemia was present in 1, smoking was present in 3 
patients, one patient was a chronic alcoholic and nobody had 
significant carotid stenosis. 
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Table-13: Penumbra with Number of risk factors 
Modifiable Risk 
factor 
No risk 
factor 
1 risk 
factor 
2 risk 
factors 
3 risk 
factors 
Penumbra positive 
patients 
2 6 0 1 
Among the penumbra positive patients, only one patient was 
having 3 modifiable risk factors (Hypertension, dyslipidemia and 
smoking). 6 patients were having only one (Hypertension-1, 
diabetes-1, alcoholism-1, coronary artery disease-1 and smoking-2) 
modifiable risk factor. Nobody among the penumbra positive 
patients had 2 modifiable risk factors (Table-13). In 2 patients no 
modifiable risk factors was found. So, if the number of modifiable 
risk factors were increasing the chances of getting significant 
penumbra were decreasing.  
Only in one patient among the penumbra positive patients, the 
blood pressure was 190/120 mmHg, whereas in all other patients 
the blood pressure was not much elevated. The highest blood sugar 
among the penumbra positive patient was 214 mg% and hence all 
the patients were having good glycemic control irrespective of their 
diabetic status. 
 
  64 
STATISTICAL ANALYSIS  
 In this study multiple variables were compared with the final 
outcome of presence of penumbra. Pearson chi-square test is used for 
comparison. Odds ratio was also calculated. In this study, p value for 
presence of penumbra in the age group of 40 to 60 years is <0.01, 
which is highly significant. P value for the age group of >60 years 
comparing with penumbra is 0.001 which is also highly significant.  
The p value for hypertension and penumbra is < 0.025 which 
is fairly significant. Diabetes has got a p value of < 0.044 which is 
also statistically significant (Table-14). 
Table-14: Significant p values 
 Prevelance of penubra Odds ratio P value 
AGE 40 T0 60 
(N=40) 
58.3% 
(n=7) 
(N=12) 
0.055  
 
 
 
<0.05 
AGE ABOVE 60 
(N=40) 
4.3% 
(n=1) 
(N=23) 
19.556 
HYPERTENSION 
(N=40) 
9.1% 
(n=2) 
(N=22) 
6.364 
DIABETES 
(N = 40) 
6.3% 
(n=1) 
(N=16) 
7.500 
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CONCLUSION 
1) This study shows male preponderance in the acute ischemic 
stroke. 
2) In this study commonest age group affected is >60 years 
(57.5%) followed by 40 to 60 years (30%) followed by <40 
years (12.5%). 
3) In this study there is slight predominance of left sided 
cerebral ischemia over right side (57.5% vs 42.5%) 
4) In this study, middle cerebral artery (80%) is commonly 
affected than anterior cerebral artery (20%). 
5) NIHSS score observed were, ≤4 - 10%, 5 to 10 – 47%, 11 TO 
15 – 40% and 16 TO 20 – 3%. 
6) All the patients with anterior circulation stroke were having 
NIHSS Score of less than 20.  
7) Even though the cohort is too small for definitive conclusion, 
there is statistically significant correlation between penumbra 
and the risk factors such as age > 40 years, hypertension and 
diabetes mellitus. 
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8) In this study most of the individuals had early CT findings 
such as dense MCA sign, insular ribbon sign, loss of 
differentiation between grey and white matter and obscuration 
of lentiform nucleus. 
9) Among the patients presented with acute ischemic stroke 
22.5% patients had ischemic penumbra. 
10) The occurrence of penumbra is common in female sex than in 
male sex. 
11) The significant penumbra is present in middle cerebral 
artery strokes, and is persistent even upto 24 hours. Hence 
we propose that there could be a paradigm shift from time 
window to tissue window and from parenchymal imaging 
to physiological & penumbra imaging in acute ischemic 
stroke. 
12) Aggressive measures to salvage the penumbra should 
continue even beyond the proposed time window. 
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TISSUE WINDOW IN STROKE  
PROFORMA 
NAME:   AGE:    SEX:  
MIN NO:      
 
SOCIO ECONOMIC CLASSIFICATION: 
 
RESIDENCE: 
 
HANDEDNESS:RIGHT/LEFT 
 
SHT: YES / NO   DM: YES /NO 
 
IHD: YES / NO 
 
SMOKER: YES/NO   ALCOHOLIC: YES /NO 
 
PREVIOUS H/O CVA: YES /NO 
 
DYSLIPIDEMIAS: YES/NO 
 
H/O BLEEDING DIASTHESIS: 
 
PREVIOUS H/O STROKE OR CAHD: 
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DRUG HISTORY: 
 
FAMILY HISTORY: YES/NO      
 
SYMPTOM ONSET (IN HOURS):  
 
ARRIVAL AT HOSPITAL (HOURS):  
 
ADMISSION BP AND PULSE RATE: 
 
CLINICAL FEATURES 
 
ADMISSION BLOOD SUGAR AND HB%: 
 
TERRITORY INVOLVED:    NIHSS SCORE:   
 
CAROTID DOPPLER:           
  
TIME OF CT (HOURS) & FINDINGS: 
 
MRI DIFFUSION & CT PERFISION DONE ON AND FINDINGS: 
 
ISCHEMIC PENUMBRA: PRESENT/ABSENT  
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study. 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including Electrophysiological examination 
I hereby consent to participate in this study. 
Signature / Thumb impression : 
Patient Name and Address :                                    Place :                      Date : 
 
 
Signature of Investigator: 
Study Investigator’s Name :                                      Place :                      Date : 
 
INFORMATION SHEET 
 We are conducting a study TISSUE WINDOW IN STROKE 
 
 The purpose of this study is to analyse the ischemic penumbra in ischemic 
stroke patients. 
 
 The privacy of the patients in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research, no personally identifiable information will be shared. 
 
 Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
 The results may be intimated to you at the end of the study period or during 
the study if anything is found abnormal which may aid in the management or 
treatment. 
 
 
 
 
 
Signature of Investigator                                             Signature of Participant 
Date: 
 
MuhŒ¢á x¥òjš got« 
MuhŒ¢á jiy¥ò 
_is g¡fthj nehÆš fh¥gh‰w¥gl¡Toa âRÉid¡ f©l¿í« MŒî 
MuhŒ¢á Ãiya« : eu«ãaš Jiw, 
br‹id kU¤Jt¡ fšÿÇ k‰W« 
uhé› fhªâ muR bghJ kU¤Jtkid, br‹id. 
g§F bgWtÇ‹ bga® : 
ghÈd« : 
g§FbgwgtÇ‹ v© : 
g§F bgWgt® ïjid ( )  F¿¡fî« 
nkny F¿¥ã£LŸs kU¤Jt MŒÉ‹ Étu§fŸ vd¡F És¡f¥g£lJ. 
v‹Dila rªnjf§fis nf£fî«, mj‰fhd jFªj És¡f§fis bgwî« 
thŒ¥gË¡f¥g£lJ.  
eh‹ ï›thŒÉš j‹Å¢irahfjh‹ g§nf‰»nw‹. vªj 
fhuz¤âdhnyh vªj f£l¤âY« vªj r£l  á¡fY¡F« c£glhkš eh‹ 
ï›thŒÉš ïUªJ Éy» bfhŸsyh« v‹W« m¿ªJ bfh©nl‹. 
ïªj MŒî r«gªjkhfnth,  ïij rh®ªj nkY« MŒî nk‰bfhŸS« 
nghJ« ïªj MŒÉš g§FbgW« kU¤Jt® v‹Dila kU¤Jt m¿¡iffis 
gh®¥gj‰F v‹ mDkâ njitÆšiy vd m¿ªJ bfhŸ»nw‹. eh‹ MŒÉš 
ïUªJ Éy»¡ bfh©lhY« ïJ bghUªJ« vd m¿»nw‹.  
ïªj MŒÉ‹ _y« »il¡F« jftšfisí«, gÇnrhjid Koîfisí« 
k‰W« á»¢ir bjhl®ghd jftšfisí« kU¤Jt® nk‰bfhŸS« MŒÉš 
ga‹gL¤â¡bfhŸsî« mij ãuRÇ¡fî« v‹ KG kdJl‹ r«kâ¡»‹nw‹.  
ïªj MŒÉš g§F bfhŸs x¥ò¡bfhŸ»nw‹. vd¡F bfhL¡f¥g£l 
m¿îiufË‹go elªJ bfhŸtJl‹ ïªj MŒit nk‰bfhŸS« kU¤Jt 
mÂ¡F c©ikíl‹ ïU¥ng‹ v‹W cWâaË»nw‹. vdJ clš 
ey«ghâ¡f¥g£lhnyh mšyJ vâ®ghuhj  tH¡fâ‰F khwhd nehŒ¡F¿ 
bj‹g£lhnyh clnd mij kU¤J mÂÆl« bjÇÉ¥ng‹ vd cWâ 
mË¡»nw‹. 
ïªj MŒÉš vd¡F ïu¤j«, áWÚ®,  v¡Þnu,  Þnf‹ k‰W« jir 
gÇnrhjid brŒJbfhŸs eh‹ KG kdJl‹ r«kâ¡»nw‹. 
 
g§nf‰gtÇ‹ ifbah¥g« ……..……….. ïl«…………….. njâ…………… 
f£ilÉuš nuif 
g§nf‰gtÇ‹ bga® k‰W« Éyhr« …………………………………………… 
MŒthsÇ‹ ifbah¥g« ……………….. ïl«…………….. njâ……………. 
MŒthsÇ‹ bga® ………………………………………… 
jftš m¿¡if 
 
br‹id kU¤Jt¡ fšÿÇ k‰W« kU¤JtkidÆš “_is 
g¡fthj nehÆš fh¥gh‰w¥gl¡Toa âRÉid¡ f©l¿í« MŒî” brŒJ 
tU»nwh«. mj‰fhf nehahËfis¤ nj®î brŒ»nwh«. 
ïªj MuhŒ¢áÆš g§nf‰F« nehahËfË‹ Égu§fŸ MŒî 
Koí« tiu ïufáakhf it¡f¥gL«. MuhŒ¢áÆ‹ Koî g‰¿a gâ¥òfŸ 
mšyJ btËpLfËš ahUila jÅ¥g£l Étu§fS« g»®ªJ 
bfhŸs¥glkh£lhJ. 
ïªj MuhŒ¢áÆš g§nf‰F« c§fŸ Koî j‹Å¢irahdJ, ïªj 
MuhŒ¢áÆš g§nf‰F« vªj neu¤âY« Éy¡»¡ bfhŸtj‰F« c§fS¡F 
thŒ¥ò cŸsJ. c§fË‹ ïªj Ô®khd¤âdhš c§fS¡F 
ï«kU¤JtkidÆš tH§f¥gL« ga‹fËš v›Éj kh‰wK« ïU¡fhJ. 
ïªj áw¥ò MŒÉ‹ KoîfŸ, ïªj MŒÉ‹ KoÉš mšyJ 
MŒÉ‹nghJ V‰gL« vâ®kiwahd Éisîfis mªnehahËÆ‹ ey‹ 
fUânah mšyJ á»¢iraË¡F« bghU£nlh nehahË¡F bjÇÉ¡f¥gL«. 
 
 
 
MŒthsÇ‹ ifbah¥g« nehahËÆ‹ ifbah¥g« 
njâ 
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INTRODUCTION Stroke is known to human race since ancient time. The 7th century great Indian
physician, Charaka described the stroke which he called “Pakshaghat” meaning hit one half of the
body. The other synonyms are ardhang or lakwa. According to Charaka, stroke affects either right or
left half of body leading to impaired movement and function of that half of the body (hemiparesis) and
difficulty in speaking which may be inability to talk (aphasia) or slurred speech (dysarthria). He had
also identified head as the vital organ, controlling the senses and nerve centers of the whole body.
These meticulous observations of stroke symptoms are relevant till now. Stroke is one of the major...
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